Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248468 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 752
- Enrollment target
NCT01248468 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 752 participants.
The verdict
NCT01248468, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 752 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
Interventions
- DRUG Placebo
- DRUG Sumatriptan
- DRUG Aspirin, acetaminophen and caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01248468
The ClinicalTrials.gov registry entry for NCT01248468 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01248468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01248468 about?
NCT01248468 is a clinical study titled "Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine". The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
What is the current status of trial NCT01248468?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 752 participants. The study started on 2010-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01248468?
The interventions under investigation include: Placebo (DRUG), Sumatriptan (DRUG), Aspirin, acetaminophen and caffeine (DRUG).
Who is sponsoring clinical trial NCT01248468?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.